Fate Therapeutics Inc (FATE)

[jondoeuk]

(OT) Cellinfinity Bio will leverage proprietary, directed evolution, identifying genetic modifications and CAR constructs that try to substantially improve engineered T- and NK cell function against solid tumours.

Their proprietary unbiased evolution technologies, such as CLASH may allow them to find universal modifications that can overcome poor tumour infiltration, immunosuppressive tumour microenvironment, and increase cell persistence https://www.nature.com/articles/s41587-022-01639-x

Also, they have licensed other novel technologies, including a genome-wide gain-of-function screening platform for boosting T-cell function https://www.cell.com/cell-metabolism/fulltext/S1550-4131(22)00053-5

In addition, a way to edit both https://www.nature.com/articles/s41592-019-0329-7